Sanofi has announced that it will lower the list price of its insulin drug, Lantus, by 78 percent and will set a $35 cap on out-of-pocket costs for all patients.
The price change and cap will go into effect starting January 1, 2024. They follow a series of moves made last year to lower the price of diabetes medicine, including the launch of an unbranded version of Lantus and a $35 cap for uninsured patients.
Yet, Olivier Bogillot, head of U.S. general medicines at Sanofi, said "the health system was unable to take advantage of it due to its inherent structural challenges."
“Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients for many years," he said. "Our decision to cut the list price of our lead insulin needs to be coupled with broader change to the overall system to actually drive savings for patients at the pharmacy counter.”
Sanofi will also cut the price of short-acting Apidra by 70 percent.
BMO Wealth Management's Carol Schleif breaks down inflation, Fed policy, earnings, AI investment, and where investors may find opportunities in today's market.
Fast Company's Christopher Zara breaks down the OpenAI-Apple legal battle, the AI chip race, and what's next for the future of artificial intelligence.
Glacier CEO Rebecca Hu-Thrams explains how AI-powered robots are making recycling smarter, reducing landfill waste, and transforming the future of waste.
Deep Fission CEO Liz Muller discusses underground nuclear reactors, powering AI, cutting energy costs, and why the future of clean power may be below ground.
Adidas shares how FIFA World Cup 2026 will drive innovation, fan engagement, and billions in opportunity with new gear, technology, and business strategy.
Kristian Kerr, Head of Macro Strategy at LPL Financial, breaks down the firm's 2026 Mid-Year Outlook, recession risks, AI, the Fed, and what's next for markets.
